John Goulding

John (Bobby) Goulding has a diverse work experience across various companies and roles. John (Bobby) began their career in 2005 as a Strategy Consultant Intern at Cambridge Antibody Technology. Later, in 2005, they worked as a Business Development Analyst Intern at Acambis, PLC.

Moving forward, Goulding served as a Scientific Advisor/Consultant at StormBio in 2008, where they contributed to a pre-clinical study for an immunotherapy against avian influenza virus. Subsequently, they joined the Centre for Respiratory Infection, Imperial College as a Post Doctoral Research Associate in 2009, where they investigated the impact of inflammatory lung diseases on the resident microbiota of the respiratory tract and collaborated on research projects.

In 2011, Goulding joined the La Jolla Institute for Allergy and Immunology as a Post Doctoral Research Fellow, focusing on studying the role of TNF receptor superfamily members in anti-viral and anti-tumor CD8 T cell immune responses. During this role, they made significant discoveries regarding CD8 T cell-dependent mechanisms protecting against respiratory viral infections.

Goulding continued their research path and joined the University of California, San Diego in 2014 as a Post Doctoral Research Scientist. Here, they aimed to investigate how micro-environmental conditions affect tissue and tumor infiltrating T cell phenotypic differentiation and functional characteristics. This research aimed to enhance the development of T cell therapies and vaccination strategies.

In 2016, Goulding joined NantKwest as a Senior Scientist in Translational Cell Therapy R&D. During their time there, they led various CAR NK cell platform development projects and directed a team of researchers, focusing on assay development, GMP clinical manufacturing, and QC/A.

In 2020, Goulding joined ThinkingNode Life Science, Inc. as an AI/ML Computational Biologist, where they developed cutting-edge AI models to generate patient-specific cell avatars and accelerate drug development timelines.

Finally, in 2021, Goulding started working at Fate Therapeutics Inc as a Principal Scientist, contributing to cell therapy drug development.

Overall, Goulding's work experience showcases their vast expertise in various scientific areas, including cell therapy, immunology, AI/ML, and respiratory infections, and their ability to lead and contribute to research projects in both academic and industry settings.

John (Bobby) Goulding has an extensive education history. John (Bobby) first pursued a Bachelor of Science (BSc) degree in Biochemistry from Imperial College London, which they completed between 2001 and 2004. Following this, they attended the University of Cambridge - Judge Business School from 2004 to 2005, where they obtained an MPhil degree in Bioscience Enterprise. Later, Goulding returned to Imperial College London for their highest level of education, earning a Doctor of Philosophy (Ph.D.) degree in Biochemistry and Inflammation Immunology specializing in viral and bacterial mucosal infections between 2005 and 2009.